| Toggle Summary
|
Boston Scientific and Osiris Therapeutics Announce Stem Cell Alliance: Alliance to develop and commercialize cardiovascular therapies using adult Mesenchymal Stem Cells
|
View HTML
|
| Toggle Summary
|
Osiris Therapeutics and JCR Pharmaceuticals Co., Ltd. announce Mesenchymal Stem Cell alliance for Japan
|
View HTML
|
| Toggle Summary
|
Osiris Therapeutics appoints C. Randal Mills President and Chief Executive Officer
|
View HTML
|
| Toggle Summary
|
Researchers Turn To Adult Stem Cells
|
View HTML
|
| Toggle Summary
|
Stem Cell Therapy Effectively Treats Heart Attacks in Animals
|
View HTML
|
| Toggle Summary
|
Osiris Therapeutics, Inc. Strengthens Executive Team.
Cary Claiborne named Chief Financial Officer. Harry Carmitchel named Chief Operating Officer.
|
View HTML
|
| Toggle Summary
|
Osiris First to Announce FDA Fast Track Designation for a Stem Cell Product.
Decision seen as a positive sign for both Osiris and the emerging stem cell industry.
|
View HTML
|
| Toggle Summary
|
Osiris Launches the First Trial Using Adult Universal Stem Cells in Cardiac Patients.
Landmark study focuses on promising therapy for the treatment of heart disease.
|
View HTML
|
| Toggle Summary
|
Osiris Cleared by FDA to Begin Stem Cell Trial for Knee Repair
The announcement marks the third adult stem cell product that Osiris has in human clinical trials.
|
View HTML
|
| Toggle Summary
|
Osiris Raises $50 Million to Commercialize First Stem Cell Products
|
View HTML
|
